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Abstract: Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role
of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve
the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic colorectal
cancer, and at present is the only antiangiogenesis agent approved for the treatment of this cancer. Aflibercept is a novel angiogenesistargeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. Here
we review the role of angiogenesis in the tumorigenesis of colorectal cancer, strategies for targeting angiogenesis, and the clinical
development of aflibercept.
Keywords: aflibercept, colorectal cancer, angiogenesis, targeted therapy, VEGF, VEGFR

Clinical Medicine Insights: Oncology 2012:6 19–30
doi: 10.4137/CMO.S7432
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Oncology 2012:6

19

Wang and Lockhart

Introduction

In the US, colorectal cancer is the third most common
cancer in both men and women and the second most
common cause of cancer mortality in both genders
combined.1 In 2011, it accounted for approximately
140,000 new cancer diagnoses and 50,000 deaths
in the US alone.1 Worldwide, more than 1.2 million
new cases, and more than 600,000 deaths was attributed to colorectal cancer at the same time.2 Therefore, colorectal cancer is a prominent global health
problem. Approximately 60% of colorectal cancer
cases are diagnosed at the locally advanced or metastatic stage.3 Metastatic colorectal cancer carries a
poor prognosis, with a 5-year survival rate of approximately 12%.3 Over the past two decades, there have
been significant advances in the treatment of metastatic colorectal cancer, one of which is the development of agents that target angiogenesis. Incorporation
of these anti-angiogenic agents into clinical practice
has led to improvements in progression-free survival
and overall survival in metastatic colorectal cancer.4
In this paper, we will review the rationale and recent
progress in targeting angiogenesis in metastatic colorectal cancer, with a special focus on the novel antiangiogenesis agent, aflibercept.

Angiogenesis and Tumorigenesis

Angiogenesis is the process of new blood vessel
formation. Blood vessels are needed for the supply of
nutrients and oxygen and the disposal of waste products, and therefore angiogenesis is essential in the
growth and development of normal tissues as well as
tumors. It is widely accepted that tumors are unable to
grow beyond 2–3 mm without blood vessels in vivo.5,6
Since 1971, when Folkman observed the importance
of angiogenesis in tumorigenesis, and predicted that
“antiangiogenesis may provide a form of cancer therapy worthy of serious exploration”, angiogenesis has
generated intense research interest.5
Angiogenesis is a highly regulated and complex
process involving a variety of proangiogenic and antiangiogenic factors and multiple signaling pathways
that intertwine and regulate each other. In a healthy
individual, there is a delicate balance between proangiogenesis and antiangiogenesis. However, as a tumor
develops, it often outgrows its vascular supply, thus
producing a hypoxic environment. Hypoxia switches
on the hypoxia-inducible factor-1 alpha system, which
20

stimulates the production of proangiogenic factors
in excess of antiangiogenic factors, or the so-called
“angiogenic switch” phenomenon, leading to pathological angiogenesis.7,8 One of the main proangiogenic pathways is mediated by the vascular endothelial
growth factor (VEGF) family, composed of six growth
factors (VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, and placenta growth factor) and three receptors (VEGFR-1, VEGFR-2, and VEGFR-3).8
The VEGF receptors are members of the transmembrane tyrosine kinase receptor family. Each VEGF
receptor is composed of several crucial domains, ie, the
immunoglobulin-like, ligand-binding extramembrane
domain, the transmembrane domain, the juxtamembrane domain, and the intracellular tyrosine kinase
domain (see Fig. 1, modified from figures by Salmon
et al,8 Cross et al,9 and Kerbel10). Circulating VEGFs
bind to the corresponding receptors, and activate the
dimerization of the receptors. Upon dimerization, the
receptors undergo conformational changes that expose
ATP binding sites on the intracellular kinase domains,
resulting in autophosphorylation of the tyrosine residues of the domains and activation of a cascade of
downstream signaling transduction pathways.
The function of VEGFR-1 is not yet fully defined.
Even though VEGFR-1 has at least 10 times stronger affinity for VEGF-A compared with VEGFR-2,
its kinase activity is weak.11 VEGFR-1 knockout
mice die in utero due to increased vascular proliferation and disorganization.12 However, embryos lacking purely the tyrosine kinase domain of VEGFR-1
can survive with normal vasculature development.13
These findings indicate that VEGFR-1 serves to
sequester VEGF-A and negatively regulates the functions of VEGFR-2 pathways.14 On the other hand,
recent research has further identified additional
roles for VEGFR-1. It has been found to be important in promoting angiogenesis and the migration
of hematopoietic stem cells.15 Therefore, the exact
role of VEFGR-1 remains unclear and needs further
investigation.
The interaction between VEGFR-2 and VEGF-A is
the best characterized ligand-receptor relationship in
the angiogenesis process. Their interaction initiates a
variety of downstream signaling pathways, resulting in
endothelial cell proliferation, differentiation, migration,
invasion, survival, and increased endothelial permeability, leading to the sprouting of new blood vessels.14,15
Clinical Medicine Insights: Oncology 2012:6
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Figure 1. Schematic illustration of the family of VEGF receptors, ligands and their functions. There are six VEGF ligands, VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, and PIGF and three main VEGF receptors, VEGFR-1, VEGFR-2, and VEGFR-3. Each VEGF ligand has specific affinity to different receptors as
illustrated. Binding of ligands to the extramembrane domain of the receptors trigger dimerization of the receptor, autophosphorylation of the tyrosine kinase
domain of the receptor, and initiate multiple downstream signal transduction pathways that result in endothelial cell proliferation, migration, survival, and more.
(The figure is modified from Salmon,8 Cross,9 and Kerbel10).
Abbreviations: VEGF, vascular endothelial growth factor; PIGF, placenta growth factors; FAK, focal adhesion kinase; PI3K, phosphatidylinositol 3-kinase.

Deletion of the VEGFR-2 gene is not compatible with
life, given that all knockout mice die in utero with
severe blood vessel deficiencies.16 On the other hand,
the ligand-receptor interactions between VEGFR-3 and
VEGF-C and VEGF-D appear to be the most important for the formation and migration of the lymphoendothelial system. Mutations in VEGFR-3 are identified
in rare cases of congenital hereditary lymphedema in
humans.17 Elevated levels of VEGFR-3 and its ligands
are found in multiple types of tumors, and are associated with lymph node metastasis.18

Angiogenesis and Colon Cancer

Studies have shown markedly increased expression of
VEGF and vascular density in primary colon tumor that
was associated with metastasis compared with that without metastasis or benign adenoma.19 It was also found
that the invasive edge of the colon tumor tissue contained
Clinical Medicine Insights: Oncology 2012:6

significantly higher vascular density than other areas
within the tumor.19 These observations all indicate that
VEGF expression is crucial in tumor metastasis. VEGF
expression is also correlated with higher risk of tumor
recurrence.19,20 Other studies have suggested a potential
role for VEGF expression as a prognostic factor and
could therefore identify high-risk patients who might
benefit from adjuvant chemotherapy in otherwise ambivalent clinical scenarios.21 Prospective studies are needed
to explore and validate these findings further. Given that
enhanced angiogenesis has been consistently associated
with poor outcomes in colorectal cancer, targeting angiogenesis was thought to be a good treatment approach.

Targeting Angiogenesis in Colon
Cancer

A variety of strategies have been investigated
to exploit the role of the VEGF pathway in
21
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colorectal cancer. To date, the most successful agent
has been bevaci-zumab, a humanized monoclonal
antibody that binds to VEGF-A and prevents interaction
between VEGF-A and VEGFR. Another targeting
strategy is to use small molecular tyrosine kinase
inhibitors, such as sunitinib and sorafenib, which bind
to the intracellular kinase domain of the receptor and
interfere with its tyrosine kinase activities essential
for downstream signaling. Additional monoclonal
antibodies against the extracellular domains of
VEGFRs are also under development. Furthermore,
agents against VEGF messenger RNAs, endogenous
antiangiogenic factors angiostatin and endostatin, and
endothelial tubulin disruption agents, as well as others
are all under active investigation at various stages of
clinical development.8
Bevacizumab is currently the only agent
approved by the US Food and Drug Administration
(FDA) specifically targeting the VEGF pathway
for the treatment of colorectal cancer. It improves
progression-free survival and overall survival when
given to patients with metastatic colorectal cancer in
combination with cytotoxic chemotherapy.4 It is usually
administrated in combination with the FOLFOX
(5-fluorouracil, leucovorin, and oxaliplatin) or
FOLFIRI (5-fluorouracil, leucovorin, and irinotecan)
chemotherapy regimens, and is therefore approved for
use in this setting.4,22,23 Agents inhibiting angiogenesis
provide different mechanisms and toxicity profiles
from traditional chemotherapy; hence, the approach of
combining angiogenesis inhibitors with chemotherapy
to achieve better disease control without an increase
in toxicity has been widely adopted. However, even
with bevacizumab, the median progression-free
survival of metastatic colorectal cancer patients
remains less than one year, with median overall
survival being approximately 2 years.4,24 Therefore,
improving the response rate, response durability, and
survival with new targeted agents remains an area
of active investigation. Aflibercept (Sanofi-aventis
and Regeneron Pharmaceuticals Inc) is a new agent
targeting the VEGF pathway. Aflibercept has recently
been shown to be well tolerated and effective in
treating patients with metastatic colorectal cancer
when combined with cytotoxic chemotherapy.25 In
the second part of this review, we will summarize
the use of aflibercept in the treatment of metastatic
colorectal cancer.
22

Small molecule tyrosine kinase inhibitors block
the tyrosine kinase activities of VEGF receptors, thus
preventing phosphorylation of signaling proteins in
the downstream pathway. Multiple tyrosine kinase
inhibitors have been developed, among which sunitinib and sorafenib have been approved by the FDA
for the treatment of metastatic renal and hepatic cancer.26–28 More tyrosine kinase inhibitors are under
active investigation. No tyrosine kinase inhibitors
have yet been approved for the treatment of colorectal
cancer. In large Phase III trials, vatalanib, a tyrosine
kinase inhibitor for all three VEGFRs, was compared
with placebo when combined with FOLFOX in both
first-line and second-line settings (CONFIRM 1 and
CONFIRM 2, respectively). Surprisingly, the primary
endpoints were not achieved in either trial (progression-free survival in CONFIRM 1 and overall survival in CONFIRM 2).29,30 Ongoing Phase I or II trials
are investigating the efficacy of other tyrosine kinase
inhibitors in colorectal cancer. It is worth noting that
the majority of tyrosine kinase inhibitors target multiple different receptor tyrosine kinases given their
structural similarity, leading to desired and undesired
“off-target” effects.
Given that antibodies against VEGF ligands have
been proven to be effective in treating metastatic
colorectal cancer, antibodies against VEGF receptors are also of great interest. Preclinical studies have
demonstrated the efficacy of a VEGFR-2 antibody in
inhibiting tumor growth, angiogenesis, metastasis,
and tumor cell survival.31,32 To date, only one Phase I
trial has been published investigating a fully humanized monoclonal antibody against VEGFR-2, ramucirumab (IMC-1121B).33 It was well tolerated without
significant toxicity in this small study. Phase II and
III studies are ongoing to incorporate ramucirumab in
the treatment of a variety of malignancies, including
colorectal, liver, kidney, prostate, ovarian, malignant
melanoma, and nonsmall cell lung cancer.34
Combining angiogenesis-targeting agents with
cytotoxic chemotherapy not only provides the advantage of nonoverlapping toxicity and therefore good
tolerance, but also serves to enhance efficacy. The
mechanism of increased efficacy with combination
therapy has been explored. Experimental models have
demonstrated that tumors have disorganized vasculature and lymphatics, leading to increased interstitial fluid pressure and poor delivery of cytotoxic
Clinical Medicine Insights: Oncology 2012:6
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No data
No data
Vandetanib

Pazopanib

Sorafenib

Notes: *The approval of bevacizumab in MBC is currently under review.
Abbreviations: chemo, chemotherapy; mCRC, metastatic colorectal cancer; NSCLC, non small cell lung cancer; MBC, metastatic breast cancer; RCC, renal cell carcinoma; GIST,
gastrointestinal stromal tumor; pNET, pancreatic neuroendocrine tumor; HCC, hepatocellular carcinoma; MTC, medullary thyroid cancer.

RCC

RCC
GIST
pNET
RCC
HCC

VEGFR-1, -2, -3, PDGFR-α, -β, c-kit,
FLT-3, RET receptor tyrosine kinase
inhibitor
VEGFR-1, -2, -3, PDGFR-β, c-kit,
FLT-3, RET receptor tyrosine kinase
inhibitor
VEGFR-1, -2, -3, PDGFR-α, -β, c-kit
receptor tyrosine kinase inhibitor
RET, VEGFR, EGFR
receptor tyrosine kinase inhibitor
Sunitinib

MTC

No data

No data

No data

No data
VEGF trap
Aflibercept

None

Superior PFS and OS compared
to placebo (Phase III)4
FDA approved
Superior PFS and OS compared
to placebo (Phase III)25
Not FDA approved
Similar efficacy to bevacizumab56
Stable disease 47% (Phase II)57
Not FDA approved
Disease control rate 65%
(Phase II)58
Not FDA approved
No data
Antibody against VEGF-A
Bevacizumab

mCRC, NSCLC, MBC*,
glioblastoma, RCC

Use in CRC—metastatic
(combined with chemo)
FDA approved
treatment
Mechanism of action
Agent

Aflibercept (VEGF trap) is a fully humanized
recombinant fusion protein composed of the
extracellular domain 2 fromVEGFR-1, the extracellular
domain 3 from VEGFR-2, and the constant region of
human immunoglobulin G1. It functions as a decoy
VEGF receptor, binds VEGF-A, VEGF-B, and
placental growth factors 1 and 2 with high affinity,
prevents their binding to native VEGF receptors, and
therefore inhibits angiogenesis. In vitro, aflibercept
is able to block VEGF-induced phosphorylation of
VEGFR-2 and VEGF-mediated cell proliferation
completely.37 In vivo, VEGF trap significantly inhibits
the growth of various tumors (including melanoma,
rhabdomyosarcoma, glioma, and neuroblastoma),
and tumor-associated angiogenesis in mouse
xenograft models.38 In neuroblastoma cells, it was
found that one of the main mechanisms of resistance
to angiogenesis inhibitors is the co-option of blood
vessels from the host.38 High-dose aflibercept can
overcome this resistance by causing regression of the
co-opted host vessels and providing near-complete
blockage of angiogenesis. This same effect is not
seen with bevacizumab or low-dose aflibercept. In
preclinical assessments, aflibercept results in stronger
angiogenesis inhibition than does bevacizumab for
several reasons, ie, at least 100–1000 times higher
affinity to the circulating VEGFs, longer half-life,
and added affinity to the placental growth factors
1 and 2.38 Table 2 is a summary of aflibercept trials
in patients with metastatic colorectal cancer. Some of
these pivotal trials are discussed in detail.

Table 1. Summary of FDA approved VEGF targeting agents in oncology and their use in colorectal cancer.

Clinical Trials with Aflibercept
in Colorectal Cancer
Pharmacodynamics and pharmacokinetics

Use in CRC—adjuvant
(combined with chemo)

c hemotherapy and hypoxia, thereby providing
resistance to chemotherapy and radiation. Jain et al,
as well as other investigators, have shown that with
anti-VEGF agents, the disorganized and inefficient
vasculature can be corrected.35 Therefore, the delivery of chemotherapy and even radiation is improved,
as demonstrated by Willett et al.35,36
Table 1 contains a list of VEGF targeted agents
currently approved by the FDA. Aflibercept is also
included for comparison, although it has not been
approved by the FDA. Their approved treatment
indications and their usage in colorectal cancer are
highlighted.

No benefit
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Table 2. Summary of clinical trials of aflibercept in metastatic colorectal cancer.
Trial

N

Dose of aflibercept

Setting

Combination
chemotherapy

Result

Phase I39

7/47a
23/38b

4 PR but none in
colorectal cancer
7 PR (4 colon) 19 SD

Phase II42

51

Phase II
(AFFIRM)46
Phase III
(VELOUR)25

230c

Single agent,
dose escalation
Second-line,
with chemo
Second-line,
Single agent
First-line,
with chemo
Second-line,
with chemo

None

Phase I59

3, 4, 7 mg/kg IV
every 2 weeks
2–6 mg/kg IV
every 2 weeks
4 mg/kg IV
every 2 weeks
4 mg/kg IV
every 2 weeks
4 mg/kg IV
every 2 weeks

614/1226d

I-LV5FU2
None
Modified
FOLFOX6
FOLFIRI

DCR 29%–30%
PFS 2–3.4 mo
Pending
PFS 6.9 mo
OS 13.5 mo
RR 19.8%
Superior to placebo

Notes: a7 out of 47 patients received aflibercept had colorectal cancer; b23 out of 38 patients received aflibercept had colorectal cancer; ctotal number of
patients in the trial, number of patients received aflibercept is unknown; d614 out of 1226 patients received aflibercept, other patients received placebo.
Abbreviations: IV, intravenous; PR, partial response; Chemo, chemotherapy; I-LV5FU2, irinotecan, leucovorin, and 5-fluorouracil (fixed standard dose);
SD, stable disease; DCR, disease control rate (any response plus stable disease); Modified FOLFOX6, 5-fluorouracil, leucovorin, and oxaliplatin; FOLFIRI;
5-fluorouracil, leucovorin, and irinotecan.

Phase I Clinical Studies

The first Phase I study, published by Lockhart et al,
aimed to evaluate the safety, pharmacokinetics, and
pharmacodynamics of intravenously administered
single-agent aflibercept.39 Forty-seven patients with a
variety of refractory solid tumors received aflibercept on
study, of whom seven had colorectal cancer. Aflibercept
was given in escalating doses from 0.3 to 7.0 mg/kg
intravenously every 2 weeks. The half-life of aflibercept
was observed to increase with dose escalation, ranging
from 1.7 (0.3 mg/kg cohort) to 7.4 days (5.0 mg/kg
cohort). Steady-state was not reached until at least 3
weeks after the first dose of aflibercept. No antibodies
against aflibercept were detected. Bound aflibercept
levels (aflibercept bound to circulating VEGF) reached
a maximum at the dose of 2 mg/kg, and free aflibercept
levels were consistently exceeding the bound levels
beyond this dose, indicating saturation and blockage of
VEGF ligands at doses $2 mg/kg. Additionally, higher
doses resulted in increasing toxicity. Therefore, 4 mg/kg
was determined to be the recommended dose for the
Phase II and III combination studies.
In this Phase I study, antitumor responses were
observed in four patients.39 One patient with malignant
thymoma and two patients with ovarian cancer had
confirmed partial responses by RECIST criteria. One
other patient with ovarian cancer had an unconfirmed
partial response. Additionally, two patients with renal
cell cancer had stable disease for more than one year.
24

Aflibercept was well tolerated. The dose-limiting
toxicities were proteinuria and rectal ulceration
observed at the dose of 7 mg/kg.39 The most common
adverse effects were fatigue (63.8%), nausea (36.2%),
and vomiting (27.7%), while the most common toxicities included dysphonia (46.8%), hypertension
(38.3%), and proteinuria (10.6%). Adverse events
were generally mild and reversible upon aflibercept
discontinuation or initiation of appropriate supportive
care, such as antihypertensives. The median onset of
hypertension was 3.5 days and that of proteinuria was
15 days.
Multiple other Phase I trials have demonstrated
the safety of combining aflibercept with cytotoxic
chemotherapy typically used for metastatic colorectal
cancer, such as FOLFOX and ILV5FU2 (5-fluorouracil, leucovorin, and irinotecan). Other chemotherapies
such as docetaxel, gemcitabine, pemetrexed, cisplatin, and temozolomide have also been combined with
aflibercept with good safety and tolerability.6,40,41

Phase II Clinical Studies

A multicenter, open-label, Phase II trial investigated
aflibercept in patients with previously treated
metastatic colorectal cancer.42 The preliminary
results from this study were reported at the
2008 American Society of Clinical Oncology
annual meeting. Fifty-one patients were enrolled
in two cohorts, ie, bevacizumab-naïve (n = 24) or
Clinical Medicine Insights: Oncology 2012:6
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bevacizumab-treated (n = 27). Single-agent aflibercept
was given at the dose of 4 mg/kg intravenously
every 2 weeks. The primary endpoints were disease
response rate and 4-month progression-free survival.
The disease control rate (including partial response
and stable disease) was 29% in bevacizumab-naïve
and 30% in bevacizumab-treated cohorts, with
median progression-free survival of 2.0 months and
3.4 months, respectively. The most common adverse
reactions were fatigue (78%), hypertension (55%),
proteinuria (49%), and headache (43%). The authors
concluded that aflibercept was well tolerated and had
modest activity against refractory/relapsed metastatic
colorectal cancer as a single agent, regardless of prior
therapy with bevacizumab.
Many other ongoing Phase II trials have found
aflibercept to be safe and well tolerated in a variety
of solid tumors, including nonsmall cell lung cancer, ovarian cancer, gynecologic soft tissue sarcoma,
transitional cell carcinoma, melanoma, and malignant
glioblastoma.43

Phase III Clinical Studies

VELOUR is a multicenter, randomized, placebocontrolled Phase III trial, with the goal of comparing the
efficacy of aflibercept versus placebo in combination
with the FOLFIRI regimen as a second-line treatment
for patients with metastatic colorectal cancer previously
treated with oxaliplatin.25 Enrolled patients included
patients with metastatic colorectal cancer, Eastern Cooperative Oncology Group performance status 0–2, and
adequate organ function after failing one oxaliplatinbased therapy. From November 2007 to March 2010,
1226 patients were enrolled, with a median age of 61
years; 58.6% were male, 97.9% of patients had a good
performance status (0–1), and 30.4% of patients had
received bevacizumab previously. Patients were randomized to receive FOLFIRI and aflibercept at 4 mg/kg
intravenously every 2 weeks (n = 614) versus FOLFIRI
and placebo (n = 612), with stratification by performance
status and prior bevacizumab. The primary endpoint was
overall survival, while the secondary endpoints included
progression-free survival, overall response rate, safety,
and aflibercept pharmacokinetics and immunogenicity.
The final data collection for primary outcomes was recently completed and presented at the
2011 meeting of the European Society for Medical
Oncology World Congress on Gastrointestinal Cancer.
Clinical Medicine Insights: Oncology 2012:6

After a median follow-up of 22.28 months, the
aflibercept group showed superior median overall
survival (13.50 months versus 12.06 months, hazards
ratio 0.817, P = 0.0032) and progression-free survival (6.90 months versus 4.67 months, hazards
ratio 0.758, P = 0.00007) compared with the placebo
group. The overall response rate in the aflibercept
group was 19.8% compared with 11.1% in the placebo group (P = 0.0001). Grade 3 or 4 adverse events
associated with aflibercept included diarrhea, fatigue,
stomatitis, infections, hypertension, abdominal pain,
neutropenia, and proteinuria (Fig. 2). Adverse events
led to treatment discontinuation in 26.6% of patients
in the aflibercept group, compared with 12.1% in the
placebo group. The authors concluded that aflibercept in combination with FOLFIRI improved overall survival and progression-free survival in patients
with metastatic colorectal cancer previously treated
with oxaliplatin. While improvement in the primary
outcomes was significant, it is unknown whether
the addition of aflibercept translated into improvement in other important clinical outcomes, such as
quality of life, considering the high rate of treatment
discontinuation. Some toxicities potentially contributing to the discontinuation rate include doubling of
the rate of diarrhea (2.5 times), febrile neutropenia
(2.0 times), stomatitis (2.7 times), and infections (2.0
times). In addition, there were several-fold increases
in hypertension (13 times) and proteinuria (6.5 times)
in patients receiving aflibercept (Fig. 2). Given its
potential use in the palliative setting, significant side
effects and potential harm to the patients’ quality of
life are crucial factors to be considered, in addition
to response rate and survivorship. More data in this
regard are expected to be available for review upon
final study publication.

Common Toxicity of Aflibercept

Aflibercept demonstrated toxicity similar to other
agents targeting the VEGF pathway, such as bevacizumab. The most common adverse events in clinical trials included hypertension, proteinuria, fatigue,
and diarrhea (Fig. 2). Table 3 compares the main
side effects observed in the Phase III VELOUR trial
(aflibercept combined with FOLFIRI) with those in
the Phase IV AVIRI study (bevacizumab in combination with FOLFIRI).22,23 This comparison could be
informative, although a cross-trial comparison carried
25
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Figure 2. Grade 3/4 adverse events with .5% differe nce in incidence between aflibercept and placebo arms in the VELOUR trial.
Notes: *FN: Febrile neutropenia. Difference in incidence of febrile neutropenia did not exceed 5% (3.9%), but was included due to its clinical significance.

inherent problems and needed to be interpreted with
great caution. For example, the patient population
differed between the two trials; VELOUR investigated the regimen as a second-line treatment, while
in the AVIRI study, bevacizumab plus FOLFIRI were
used in the first-line setting. As shown in Table 3, the
most noticeable difference was that aflibercept trials
revealed a numerically higher risk of hypertension and
proteinuria of any grade and grade 3/4. Proteinuria of
any grade was reported in 62% of patients receiving
aflibercept, while approximately 8% had proteinuria
of more than grade three. In the AVIRI study, bevacizumab was associated with an incidence of proteinuria of any grade and proteinuria $grade 3 of 3.3% and
1.9%, respectively. Any grade of hypertension was
reported in 41% of patients on the aflibercept arm,
compared with close to 20% with $grade 3. In patients
receiving bevacizumab, 28% developed hypertension of any degree, while 5%–10% developed more
severe hypertension ($grade 3). In Phase III trials of
other small molecule tyrosine kinase inhibitors, such
as sunitinib and sorafenib, which shared many of the
toxicities of VEGF antagonists, the rates of hypertension were found to be closer to that of bevacizumab.
Any grade and grade 3/4 of hypertension were found
in 24% and 8% of patients taking sunitinib, whereas
26

these were observed in 17% and 4% of patients
on sorafenib, respectively.26,27 The reason for this
increased toxicity in the aflibercept group was unclear,
but the enhanced affinity of aflibercept for VEGF-A
and stronger inhibition of the VEGF pathway might
play a role. Additionally, it is worth noting that in the
VELOUR trial, the rate of proteinuria found in the
placebo arm was higher than expected, ie, 40.7% with
any grade and 1% with grade 3/4. Gastrointestinal perforations, fistula, and wound healing complications
were rare events and occurred in less than 1% of the
patients.
Adverse events, such as hypertension, were
generally manageable with medications. Currently,
there are no standard guidelines on management
for VEGF inhibitor-associated hypertension. In the
initial pivotal trial investigating the combination of
bevacizumab and chemotherapy in the treatment of
metastatic colorectal cancer, all hypertensive episodes
were manageable with standard antihypertensives
such as angiotensin-converting enzyme inhibitors,
calcium channel blockers, and diuretics.4 In recent
years, advantages of angiotensin-converting enzyme
inhibitors and angiotensin II receptor blockers in
this population have been identified, including a low
interaction potential with antiangiogenesis agents,
Clinical Medicine Insights: Oncology 2012:6
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Table 3. Comparison of grade 3 or 4 adverse events in
phase III trials with aflibercept vs. bevacizumab.24,25
Adverse events

Aflibercept +
FOLFIRI (%)

Bevacizumab +
FOLFIRI (%)

Neutropenia
Febrile neutropenia
Diarrhea
Fatigue
Hypertension
(any grade)
Hypertension
(grade 3/4)
Venous thrombosis
Arterial thrombosis
Hemorrhage
(grade 3/4)
Proteinuria
(any grade)
Proteinuria
(grade 3/4)
Gastrointestinal
perforation
Fistula
Wound healing issues

36.7
5.7
19.3
16.9
41.4

29
6
12
10
28

19.3

5*

7.9
1.8
2.9

18
4
4.0

62.2

3.3

7.9

1.9

0.5

2

0.3
0.3

1
,1

Note: *Other large phase III trials of similar regimen have reported a rate
of grade 3 or 4 hypertension to be higher than 10%.4,22

the benefit of addressing treatment-induced proteinuria concurrently, and prevention of the expression of
plasminogen activator inhibitor-1.44,45 Plasminogen
activator inhibitor-1 was often found to be stimulated
by antiangiogenesis agents, resulting in resistance
of fibrinolysis and a higher risk of thrombosis.44,45
Furthermore, in multiple cancer cell lines and animal
models, angiotensin-converting enzyme inhibitors
and angiotensin II receptor blockers were found to
delay tumor cell growth, which was thought to be due
to the effects of angiotensin II inhibition.45 Therefore,
some researchers advocated angiotensin-converting
enzyme inhibitors or angiotensin II receptor blockers
to be among the first-line therapies for hypertension
associated with angiogenesis blockers.44,45

Current Place of Aflibercept in
Treatment of Metastatic Colorectal
Cancer

Given the preliminary positive results of the Phase
III VELOUR trial, Sanofi-Aventis and Regeneron
Pharmaceuticals Inc, are preparing to submit regulatory applications for marketing approval to the US
FDA and European Medicines Agency later this year.
Clinical Medicine Insights: Oncology 2012:6

If successful, aflibercept will become the second
VEGF pathway targeted agent approved for the treatment of metastatic colorectal cancer. It is anticipated
that this agent would be administered along with
FOLFIRI chemotherapy in patients whose tumors
have progressed despite first-line therapy.

Future Directions

Multiple Phase I, II, and III trials are ongoing to
investigate the effects of aflibercept alone or in
combination with chemotherapy to treat a variety
of malignancies. The AFFIRM trial is an ongoing
Phase II study investigating the combination of
aflibercept with FOLFOX as the first-line treatment
for metastatic colorectal cancer.46 The trial has
completed accrual and its preliminary results are
expected in late 2011. Given that bevacizumab
showed a 5-month improvement in overall survival
when combined with irinotecan, bolus fluorouracil,
and leucovorin in an untreated population, it is of
great interest how aflibercept would perform in this
similar clinical setting.4 When more new agents
targeting the VEGF pathway become available, it
would be prudent to compare the efficacy of these new
agents with existing therapies, such as bevacizumab.
The preliminary results of the VELOUR trial are
comparable with those of E3200, the Phase III trial
comparing FOLFOX with or without bevacizumab as
second-line therapy in patients who have progressed
on irinotecan-based therapy.47 The optimal sequence
of these biological agents, possibility of crossresistance, and utility of the continuation of VEGF
inhibition after progression are also important clinical
questions that need to be answered.
Another area to be explored is the combination of
VEGF and EGFR (endothelial growth factor receptor)
blockade. Preclinical data and Phase II BOND-2 trial
provided encouraging results on the combination of
bevacizumab and cetuximab (an endothelial growth
factor receptor inhibitor) with irinotecan in patients with
metastatic colorectal cancer refractory to irinotecan.48
However, large Phase III trials disappointingly showed
increased toxicity with shortened progression-free
survival when panitumumab or cetuximab was added
to bevacizumab with chemotherapy.49,50 The reasons
of these failed Phase III trials are unclear, and it is also
unknown that if aflibercept can perform better in a
similar situation.
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Table 4. Summary of phase III trials of aflibercept.
Trial

N

Targeted disease

Setting

Regimen

Endpoints

Status

1226

Metastatic
colorectal
cancer

Second-line

FOLFIRI
± aflibercept

Completed, awaiting
publication.
(superior OS
and PFS)

VITAL54

900+

Second-line

Docetaxel
± aflibercept

VENICE53

1200+

Locally advanced
or metastatic
non-smallcell lung cancer
Metastatic androgen
independent prostate
cancer

First-line chemo
after failing
androgen

Docetaxel/
Prednisone
± aflibercept

VANILLA60

546

Metastatic
pancreatic
adenocarcinoma

First-line

Gemcitabine
± aflibercept

OS*
PFS
ORR
Safety
Immunogenicity
OS*
PFS
ORR
Symptoms
OS*
PSA
Pain
Skeletal related
events
OS*
PFS
ORR
Safety
Clinical benefit
based on symptoms
Immunogenicity

VELOUR

25

Completed, awaiting
publication. (OS no
difference, superior
PFS and ORR)
Ongoing, results
are expected in
June 2012
Early termination
in 2009 (failure to
achieve primary
outcomes)

Notes: +Estimated enrollment; *primary end point(s), the rest are secondary endpoints.
Abbreviations: FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; OS, overall survival; PFS, progression free survival; ORR, overall response rate; PSA,
prostate specific antigen.

The efficacy of anti-VEGF in the adjuvant setting
is of interest to researchers due to the good performance of bevacizumab in metastatic colorectal cancer.
However, bevacizumab failed to show benefits when
combined with cytotoxic chemotherapy as adjuvant
therapy in two large, randomized, Phase III trials.51,52
Considering that aflibercept is a much stronger VEGF
inhibitor than bevacizumab, one may speculate on its
possible efficacy in the adjuvant setting to treat these
microscopic metastases.
Other active Phase III studies on aflibercept
include the VENICE trial, evaluating aflibercept
versus placebo combined with docetaxel and prednisone in treating patients with metastatic androgen
independent prostate cancer, and the VITAL trial,
evaluating aflibercept versus placebo in combination with docetaxel as a second-line treatment
for patients with metastatic nonsmall cell lung
cancer.53,54 Table 4 is a summary of the ongoing
Phase III trials incorporating aflibercept. Although
the preliminary results from the VITAL trial indicated that the addition of aflibercept to docetaxel
failed to improve overall survival, its progressionfree survival and overall response rate were superior
28

to placebo. Final results remain to be seen after their
data are published.54
Given the significantly increased toxicity associated with aflibercept and other VEGF inhibitors, it is
important to identify patients who would benefit most
from VEGF inhibitors and avoid treatment-related
toxicities in patients who will not benefit. Circulating
biomarkers, such as VEGF and VEGFR2, have been
investigated, but have not consistently demonstrated
prognostic value.55 There is ongoing research to identify more reliable factors to assist in these important
clinical decisions.

Conclusion

Aflibercept is a new agent targeting the VEGF pathway in the treatment of solid tumors. The VELOUR
trial showed the efficacy of aflibercept in improving
progression-free survival and overall survival when
combined with FOLFIRI as a second-line treatment for
metastatic colorectal cancer. Aflibercept is also associated with increased toxicities, such as proteinuria
and hypertension. Ongoing Phase II and Phase III trials will determine further the role of aflibercept in the
treatment of colorectal cancer and other solid tumors.

Clinical Medicine Insights: Oncology 2012:6

Aflibercept in metastatic colorectal cancer

Disclosures

Author(s) have provided signed confirmations to the
publisher of their compliance with all applicable legal
and ethical obligations in respect to declaration of conflicts of interest, funding, authorship and contributorship, and compliance with ethical requirements in
respect to treatment of human and animal test subjects.
If this article contains identifiable human subject(s)
author(s) were required to supply signed patient consent
prior to publication. Author(s) have confirmed that the
published article is unique and not under consideration
nor published by any other publication and that they
have consent to reproduce any copyrighted material.
The peer reviewers declared no conflicts of interest.

References

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics. CA Cancer J Clin.
2011;61:212–36.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90.
3. American Cancer Society. Cancer Facts and Figures 2011. Available from:
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/
documents/document/acspc-029771.pdf. Accessed November 18, 2011.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J
Med. 2004;350:2335–42.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med.
1971;285:1182–6.
6. Chu E. An update on the current and emerging targeted agents in metastatic
colorectal cancer. Clin Colorectal Cancer. July 11, 2011. [Epub ahead of
print.]
7. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer.
Oncogene. 2003;22:6549–56.
8. Salmon JS, Lockhart AC, Berlin J. Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest. 2005;23:712–26.
9. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor
signal transduction. Trends Biochem Sci. 2003;28:488–94.
10. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–49.
11. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in
the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19:
5598–605.
12. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1
receptor tyrosine kinase in regulating the assembly of vascular endothelium.
Nature. 995;376:66–70.
13. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the
tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A. 1998;95:9349–54.
14. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/
vascular endothelial growth factor (VEGF) peceptor-1 down-modulates
VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not
migration, through phosphatidylinositol 3-kinase-dependent pathways.
J Biol Chem. 2001;276:26969–79.
15. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway
in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.
16. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation
and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62–6.
17. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital
hereditary lymphedema caused by a mutation that inactivates VEGFR3
tyrosine kinase. Am J Hum Genet. 2000;67:295–301.

Clinical Medicine Insights: Oncology 2012:6

18. Achen MG, Williams RA, Minekus MP, et al. Localization of vascular
endothelial growth factor-D in malignant melanoma suggests a role in
tumour angiogenesis. J Pathol. 2001;193:147–54.
19. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of
vascular endothelial growth factor and its receptor, KDR, correlates with
vascularity, metastasis, and proliferation of human colon cancer. Cancer
Res. 1995;55:3964–8.
20. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of
vascular endothelial growth factor as prognostic factors in node-negative
colon cancer. Arch Surg. 1997;132:541–6.
21. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular
endothelial growth factor can predict event-free survival in stage II colon
cancer. Clin Cancer Res. 2000;6:2803–7.
22. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of
irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line
treatment of metastatic colorectal cancer: results from the BICC-C Study.
J Clin Oncol. 2007;25:4779–86.
23. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination
with oxaliplatin-based chemotherapy as first-line therapy in metastatic
colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:
2013–9.
24. Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab
in combination with infusional fluorouracil, leucovorin and irinotecan
(FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009;77:
113–9.
25. Van Cutsem E, Tabernero J, Lakomy R. Intravenous aflibercept versus
placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line
treatment of metastatic colorectal cancer (MCRC): results of a multinational
Phase III trial (EFC10262-VELOUR). Ann Oncol. 2011:22.
26. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in
metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.
27. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med. 2007;356:125–34.
28. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular
carcinoma. N Engl J Med. 2008;359:378–90.
29. Hecht JR, Trarbach T, Jaeger E. A randomized, double-blind, placebocontrolled, phase III study in patients (Pts) with metastatic adenocarcinoma
of the colon or rectum receiving first-line chemotherapy with oxaliplatin/
5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol. 2005;23 Suppl 2:Abstr LBA3.
30. Kohne C, Bajetta E, Lin E. Final results of CONFIRM 2: A multinational,
randomized, double-blind, phase III study in 2nd line patients (pts) with
metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK
222584 (PTK/ZK) or placebo. J Clin Oncol. 2007;25 Suppl 18S:4033.
31. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis
and growth of several mouse and human tumors. Cancer Res. 1999;59:
5209–18.
32. Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel
attack on angiogenesis. Future Oncol. 2010;6:1085–94.
33. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic
study of ramucirumab (IMC-1121B), a fully human immunoglobulin
G1 monoclonal antibody targeting the vascular endothelial growth factor
receptor-2. J Clin Oncol. 2010;28:780–7.
34. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF
treatment with large molecules. Nat Rev Clin Oncol. 2009;6:507–18.
35. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy:
a new paradigm for combination therapy. Nat Med. 2001;7:987–9.
36. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGFspecific antibody bevacizumab has antivascular effects in human rectal cancer.
Nat Med. 2004;10:145–7.
37. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker
with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99:11393–8.
38. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression
of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A.
2002;99:11399–404.

29

Wang and Lockhart
39. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous
vascular endothelial growth factor trap, aflibercept, in patients with advanced
solid tumors. J Clin Oncol. 2010;28:207–14.
40. Townsley CA, Siu LL, Pedro-Salcedo MS. A Phase I study of aflibercept,
pemetrexed, and cisplatin in patients with advanced solid tumors. J Clin
Oncol. 2010;28 Suppl 15:Abstr 2536.
41. De Groot JF, Cloughesy T, Lieberman FS. Phase I study of aflibercept and
temozolomide in newly diagnosed, high-grade glioma. J Clin Oncol. 2011;
Suppl 29:Abstr 2043.
42. Tang P, Cohen SJ, Bjarnason GA. Phase II trial of aflibercept (VEGF Trap)
in previously treated patients with metastatic colorectal cancer (MCRC):
a PMH phase II consortium trial. J Clin Oncol. 2008;Suppl 26:Abstr 4027.
43. Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications
of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010;73:
449–56.
44. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for
bevacizumab-induced hypertension. Ann Pharmacother. 2006;40:2278–9.
45. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in
angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807–15.
46. US National Institutes of Health. Study of Aflibercept and Modified FOLFOX6 As First-line treatment in patients with metastatic colorectal cancer
(AFFIRM). Available from: http://clinicaltrials.gov/ct2/show/NCT00851084.
Accessed September 21, 2011.
47. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination
with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously
treated metastatic colorectal cancer: results from the Eastern Cooperative
Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.
48. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab,
bevacizumab, and irinotecan compared with cetuximab and bevacizumab
alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin
Oncol. 2007;25:4557–61.
49. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab
in metastatic colorectal cancer. N Engl J Med. 2009;360:563–72.
50. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and
bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:
672–80.
51. Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing
bevacizumab in stages II and III carcinoma of the colon: results of NSABP
protocol C-08. J Clin Oncol. 2011;29:11–6.
52. Investor update. Available from: http://www.roche.com/investors/ir_update/
inv-update-2010-09-18b.html. Accessed September 28, 2011.

53. US National Institutes of Health. Aflibercept in Combination With
Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE).
Available from: http://clinicaltrials.gov/ct2/show/NCT00519285. Accessed
September 21, 2011.
54. US National Institutes of Health. A study of aflibercept versus placebo in
patients with second-line docetaxel for locally advanced or metastatic nonsmall-cell lung cancer (VITAL). Available from: http://clinicaltrials.gov/
ct2/show/NCT00532155. Accessed September 21, 2011.
55. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role
in the development of VEGF inhibitors. Br J Cancer. 2010;102:8–18.
56. Hecht JR, Yoshino T, Mitchell EP, et al. A randomized, phase IIb study of
sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)
versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic
colorectal cancer (mCRC): Interim results. J Clin Oncol. 2010;28 Suppl 15:
Abstr 3532.
57. Samson B, Latreille J, Nguyen NT, Sperlich C, Berbiche D, Tournigand C.
SUNCAP, a phase II study with sunitinib and capecitabine in patients with
metastatic colorectal cancer (MCRC) refractory to previous treatment with
5FU/irinotecan/oxaliplatin. J Clin Oncol. 2011;29 Suppl 4:Abstr 545.
58. Ychou M, Bouche O, Thézenas S, et al. Final results of a multicenter phase II
trial assessing sorafenib (S) in combination with irinotecan (i) as second- or
later-line treatment in metastatic colorectal cancer (mCRC) patients (pts)
with KRAS-mutated tumors (mt; NEXIRI). J Clin Oncol. 2011;29 Suppl:
Abstr e14002.
59. Rixe O, Verslype C, Khayat D, et al. A phase I dose escalation (DE) and
pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus
irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with
advanced solid tumors (STs). J Clin Oncol. 2008;26 Suppl:Abstr 3557.
60. US National Institutes of Health. Aflibercept compared to placebo in term of
eficacyin patients treatedwith gemcitabine for metastaticpancreatic cancer
(VANILLA). Available from: http://www.clinicaltrials.gov/ct2/show/
NCT00574275. Accessed September 21, 2011.

Publish with Libertas Academica and
every scientist working in your field can
read your article
“I would like to say that this is the most author-friendly
editing process I have experienced in over 150
publications. Thank you most sincerely.”
“The communication between your staff and me has
been terrific. Whenever progress is made with the
manuscript, I receive notice. Quite honestly, I’ve
never had such complete communication with a
journal.”
“LA is different, and hopefully represents a kind of
scientific publication machinery that removes the
hurdles from free flow of scientific thought.”

Your paper will be:
•
Available to your entire community
free of charge
•
Fairly and quickly peer reviewed
•
Yours! You retain copyright
http://www.la-press.com

30

Clinical Medicine Insights: Oncology 2012:6

